Pancreas Spring Meeting
Göttingen 2017

11–12 May 2017 • Göttingen/Germany

Congress details

Scientific programme

11:30–12:00 Registration and welcome coffee
12:00–12:15 Opening
Welcome note by Heyo Kroemer
Dean of the University Medical Centre Göttingen

Welcome note by Volker Ellenrieder and Michael Ghadimi
Conference Chairs
12:15–13:20
Chairs
Medical therapy and diagnostics in PDAC and NET
R. M. Schmid (Munich/DE), P. Michl (Halle a. d. Saale/DE)
12:15 Molecular diagnosis of pancreatic cancer and precursor lesions
M. Goggins (Baltimore, MD/US)
12:45 Facts and fiction about pancreatic neuroendocrine neoplasms in 2017
G. Capurso (Rome/IT)
13:05 Göttingen pancreas cancer programme
P. Ströbel (Göttingen/DE)
13:20–14:30 Lunch break and visit of the poster and industrial exhibition
14:30–16:00
Chairs
Innovative surgery and imaging in PDAC
J. Gaedcke, F. Alves (Göttingen/DE)
14:30 Image guided surgery of the pancreas
A. Vahrmeijer (Leiden/NL)
15:00 Challenges and limits in pancreatic surgery 2017
M. Ghadimi (Göttingen/DE)
15:20 The pig as a model for human cancers?
T. Flisikowska (Freising/DE)
15:40–17:10 Poster session
17:10–17:30 Coffee break and visit of the poster and industrial exhibition
17:30–19:00
Chairs
Tumor microenvironment and stem cells
J. Mayerle (Munich/DE), N.N.
17:30 Role of endogenous deaminases in pancreatic cancer and immune response
A. Rhim (Houston, TX/US)
18:00 Deconstructing the stroma in pancreatic cancer – a genetic approach
C. Guerra (Madrid/ES)
18:20 Cellular plasticity in pancreatic cancer aetiology and therapy response
J. Siveke (Essen/DE)
18:40 Therapeutic implications of cellular heterogeneity and plasticity in pancreatic cancer
C. Heeschen (London/GB)
19:30 Conference dinner at the restaurant of the German Theatre Göttingen
09:00–10:30
Chairs
Epigenetics
A. König, M. Dobbelstein (Göttingen/DE)
09:00 The epigenomics landscape of pancreatic cancer
R. Urrutia (Rochester, NY/US)
09:30 Context-dependent EZH2 activity in pancreatic plasticity
E. Hessmann (Göttingen/DE)
09:50 Concepts to target pancreactic cancer
G. Schneider (Munich/DE)
10:10 Epigenetic regulation of cell fate specification
S. Johnsen (Göttingen/DE)
10:30–10:50 Coffee break and visit of the poster and industrial exhibition
10:50–12:10
Chairs
Translational medicine
M. Buchholz (Marburg/DE), A. Rhim (Houston, TX/US)
10:50

Predictive radiomics in pancreatic cancer
E. Collisson (San Francisco, CA/US)
11:10

The basal-like phenotype of pancreatic cancers – clinical implications
P. Real (Madrid/ES)
11:30 Pharmacological targeting of stellate cells for therapeutic gain in pancreatic adenocarcinoma
C. Bousquet (Toulouse/FR)
11:50 Drug scavenging of fibroblasts in pancreatic cancer
A. Neesse (Göttingen/DE)
12:10-12:30 Coffee break and visit of the poster and industrial exhibition
12:30–13:40
Chairs
Immunology
V. Ellenrieder, S. Johnsen (Göttingen/DE)
12:30 Targeting the squamous subtype of pancreatic cancer
P. Bailey (Glasgow/GB)
13:00 Immune regulation of pancreatic plasticity and carcinogenesis
M. Pasca di Magliano (Ann Arbor, MI/US)
13:20 MIF signalling pathway as a pathogenic driver and potential target in pancreatic cancer
S. P. Hussain (Bethesda, MD/US)
13:40–13:50 Summary and closing remarks
13:50–14:30 Lunch and farewell

Poster Sessions

Session 1 • Pancreatic cancer – genetics and epigenetics (P 1–P 13)
Chairs H. Griesmann (Halle a. d. Saale/DE), F. Wegwitz (Göttingen/DE)
P 1 Histone demethylator KDM4D may serve as a novel prognostic factor in pancreatic adenocarcinomas
J. Isohookana, P. Karihtala, K. M. Haapasaari (Oulu/FI), Y. Soini (Kuopio/FI)
P 2 Functional characterization of EZH2 in pancreatic carcinogenesis
B. Steuber, M. C. Hasselluhn, N. M. Chen, A. Neesse, S. Johnsen, V. Ellenrieder, E. Hessmann (Göttingen/DE)
P 3 The role of Prrx1 to bypass oncogene-induced senescence in pancreatic cancer
K. Feldmann, A. Nomura, Z. Dantes, R. M. Schmid, D. Saur, G. Schneider M. Reichert (Munich/DE)
P 4 Molecular subtypes of pancreatic adenocarcinoma
L. Beißbarth, P. Ströbel, T. Beißbarth (Göttingen/DE)
P 5 Functional characterization and clinical relevance of candidate genes in pancreatic neuroendocrine cancer
M. Hutzler, H. Schmidt, R. Diels (Marburg/DE), R. Lawlor, A. Scarpa (Verona/IT) T. Gress, M. Buchholz (Marburg/DE)
P 6 Combining oncogenic Kras mutation and LKB1 inactivation in pancreatic ductal cells provides evidence that intraductal papillary mucinous neoplasms originate from pancreatic duct glands
E. Ghurburrun, L. Collet, F. P. Lemaigre, I. Borbath, P. Jacquemin (Brussels/BE)
P 7 ATM-deficiency generates genomic instability in PDAC and sensitizesfor new therapeutic options
L. Perkhofer, P. O. Frappart, A. Kleger (Ulm/DE), A. Schmitt (Cologne/DE)
P 8 Loss of 4E-BP1-mediated translational control favors DNA replication in pancreatic cancer
D. Müller, T. Goullet de Rugy, R. Samain, S. Shin, R. Baer (Toulouse/FR), L. Masvidal-Sanz (Stockholm/SE), F. Grimal, H. Avet-Loiseau J. Guillermet-Guibert (Toulouse/FR), Y. Tsukumo (Tokyo/JP), S. Cassant-Sourdy C. Jean (Stockholm/SE), N. Sonenberg (Montreal/CA), J. S. Hoffmann (Toulouse/FR) O. Larsson (Stockholm/SE), C. Bousquet, S. Pyronnet, Y. Martineau (Toulouse/FR)
P 9 Targeting oncogenic EZH2 histone methyltransferase activity in pancreatic cancer cell plasticity
S. Patil, H. Witte, A. Neesse, S. Johnsen, V. Ellenrieder, E. Hessmann (Göttingen/DE)
P 10 Characterization of p53-dependent oncogenic EZH2-activity in pancreatic cancer
L. Versemann, H. Witte, W. Kopp, J. Spitalieri, V. Ellenrieder, E. Heßmann (Göttingen/DE)
P 11 Role of mir34a in Kras driven pancreatic cancer initiation and progression
A. Hidalgo Sastre (Munich/DE)
P 12 Cooperation of MDM2 with polycomb repressors in the control of pancreatic cancer cell proliferation
S. Rodewald, M. Wienken, A. Dickmanns, C. Bierwirth, M. Dobbelstein (Göttingen/DE)
P 13 CUX1 cooperates with K-Ras in the tumor progression of pancreatic cancer in vivo
H. Griesmann, S. Mühl, K. Theuerkorn (Halle a. d. Saale/DE), B. Sipos (Tübingen/DE) P. Michl (Halle a. d. Saale/DE)
Session 2 • Stem cells and environment (P 14–P 25)
Chairs P. Hermann (Ulm/DE), M. Reichert (Munich/DE)
P 14 Positive feedback loops of enhanced canonical wnt confer stemness traits to pancreatic cancer cells
M. Ilmer, B. Renz, J. Wang, J. Werner, M. Weniger (Munich/DE), E. Alt (New Orleans/US) A. Bazhin, J. d'Haese (Munich/DE), J. Vykoukal (Houston/US)
P 15 The ISG15-mediated ubiquitin-like modification process known as ISGylation is important in the biology of pancreatic cancer stem cells
L. Martin-Hijano, S. Alcala, M. Vallespinos, B. Sainz Jr. (Madrid/ES)
P 16 Development of a pancreatic cancer stem cell platform for drug discovery
S. Valle, S. Alcalá, M. î Fernández-Moreno, B. Sainz (Madrid/ES)
P 17 TRAIL inducible NF-κB/CCL20 bifunctional cross-signaling pathway in PDAC between tumor and immune cells
C. Geismann (Kiel/DE), G. Schneider (Munich/DE), A. Arlt (Kiel/DE)
P 18 Characterizing the tumor-associated macrophage polarization in pancreatic ductal adenocarcinoma
P. Cheung (Essen/DE), F. Neff (Heidelberg/DE), D. G. Kirsch (Durcham/US) D. Saur (Heidelberg, Munich/DE), R. Schmid, A. Bahzin (Essen, Heidelberg, Munich/DE) M. F. Heikkenwalder (Heidelberg, Munich/DE) J. T. Siveke (Essen, Heidelberg, Munich/DE)
P 19 Role of TRAIL death receptor 2 in liver metastasis of pancreatic cancer
L. Miarka, C. Hauser, K. Legler, J. H. Egberts, O. Helm (Kiel/DE), W. Mikulits (Vienna/AU) A. Trauzold, S. Sebens (Kiel/DE)
P 20 Lipoxin A4 inhibits pancreatic stellate cell differentiation and inhibits pancreatic tumor growth in vivo
J. Schnittert, M. Heinrich, J. Prakash (Enschede/NL)
P 21 Cellular deconvolution and expression analysis of Stomal and Epithelial cells directly isolated from human Pancreatic Ductal
Adenocarcinoma (PDAC)
E. Espinet, Z. Gu, C. D. Imbusch, V. Vogel, C. Klein, J. Yang O. Espinosa, N. A. Giese, O. Strobel, T. Hackert, A. Muchenhuber, M. Schlesner, B. Brors, M. Büchler, R. Eils, W. Weichert, M. R. Sprick, A. Trumpp (Heidelberg/DE)
P 22 Functional characterization of NFATc1 in the development of pancreatic cancer-associated cancer cachexia
D. Spyropoulou, R. Goetze, D. Saul, S. Singh, C. Kellner, W. Kopp, S. Patil, J. Spitalieri, Z. Thang, V. Ellenrieder, E. Hessmann (Göttingen/DE)
P 23 Telomerase inhibition leads to elimination of cancer stem cells in pancreatic ductal adenocarcinoma
K. Walter (Ulm/DE), M. S. Ventura Fereira (Aachen/DE), V. Usachov, C. Günes, A. Kleger T. Seufferlein (Ulm/DE), B. Sainz (Madrid/ES), F. Beier (Aachen/DE), P. Hermann (Ulm/DE)
P 24 Characterization of NFATc1/Smad3 complexes in pancreatic cancer
M. C. Hasselluhn, H. Bohnenberger, C. Lenz, S. Johnsen, V. Ellenrieder E. Hessmann (Göttingen/DE)
P 25 Combination of PD1 and CD96 blockade improves survival in a resectable murine model of pancreatic cancer
J. Brooks, B. Fleischmann-Mundt, N. Woller, M. P. Manns, S. Kubicka E. Gürlevik, F. Kühnel (Hannover/DE)
Session 3 • Translational medicine (P 26–P 38)
Chairs M. Saborowski (Hannover/DE), C. Pilarsky (Erlangen/DE)
P 26 Use of the liquid fiducial marker BioXmark for high-precision radiotherapy of a pancreatic tumor mouse model
S. Dobiasch (Munich/DE), S. Kampfer (Munich, Garching/DE), R. Burkhardt J. J. Wilkens (Munich, Garching, Neuherberg/DE), S. E. Combs (Munich, Neuherberg/DE)
P 27 Identification of neuroinvasion-promoting mutations in the pancreatic cancer by piggybac-transposon mutagenesis
P. Stupakov, I. E. Demir, I. Kröger, S. Teller, R. Rad, H. Friess, G. O. Ceyhan (Munich/DE)
P 28 Fluorescence guided surgery directed by pre-operative multispectral, optoacoustic tomography (MSOT)
J. Napp (Göttingen/DE), M. Stammes (Leiden, Enschede/NL), J. Claussen, T. Devling (Munich/DE), A. Chan (Enschede/NL), L. F. de Geus-Oei (Leiden/NL) F. Alves (Göttingen/DE)
P 29 Epithelial-to-mesenchymal-transition regulating microRNAs are potential biomarkers for diagnosis and prognosis of pancreatic ductal adenocarcinoma
M. Träger, J. Rehkämper, K. Steinestel, T. Vowinkel, E. Wardelmann, N. Senninger S. Dhayat (Münster/DE)
P 30 Valosin-containing protein (VCP) is crucial for the proliferation and viability of the pancreatic cancer cells
B. P. Kaistha, S. Schimanski, T. Gress, M. Buchholz (Marburg/DE)
P 31 targeting integrin alpha5 as a novel strategy to treat pancreatic tumor in vivo
P. R. Kuninty (Enschede/NL), S. W. L. De Geus (Leiden/NL) R. Bansal, G. Storm (Enschede/NL), P. Kuppen (Leiden/NL), A. Vahrmeijer (Leiden/NL) A. Ostman (Stockholm/SE), C. F. Sier (Leiden/NL), J. Prakash (Stockholm, Enschede/SE, NL)
P 32 Translational application of a modified organoid culture system from pancreatic cancer patients
Z. Dantes, M. Wirth, K. Feldmann, A. Nomura, M. Dantes, A. Muckenhuber, K. Steiger O. Strobel, M. Martignoni, G. O. Ceyhan, J. Siveke, S. von Delius, W. Weichert R. Braren (Munich/DE), A. K. Rustgi (Philadelphia/US), R. Schmid D. Saur, G. Schneider (Munich/DE), M. Reichert (Munich/DE, Philadelphia/US)
P 33 STAT3 facilitates resistance of pancreatic cancer cells to chemoradiotherapy
A. L. Jakubzik, M. Spitzner, P. E. Marquet, E. Hessmann, M. Rave-Fränk, B. M. Ghadimi A. König, M. Grade (Göttingen/DE)
P 34 Exploring the molecular mechanism of PDAC resistance to MEK inhibitor
J. Gu (Essen, Heidelberg/DE), A. Herner (Düsseldorf/DE) X. Zhang, L. Dierichs (Essen, Heidelberg/DE), N. Teichmann, I. Heid R. Braren (Munich/DE), V. Marquardt, D. Picard, P. David, M. Remke (Düsseldorf/DE) M. Trajkovic-Arsic, J. T. Siveke (Essen, Heidelberg/DE)
P 35 Preoperative serum thymidine kinase activity as a novel monitoring, prognostic and predictive biomarker in pancreatic cancer
K. Felix (Heidelberg/DE), S. Dobiasch (Heidelberg, Munich/DE), T. Hackert F. Bergmann (Heidelberg/DE), M. Neumüller, M. Bergqvist (Uppsala/SE) O. Strobel (Heidelberg/DE)
P 36 Relevance of Sp binding site polymorphism in WWOX for treatment outcome in pancreatic cancer
M. A. Schirmer, C. M. Lüske, S. Roppel, A. Schaudinn, C. Zimmer, R. Pflüger, M. Haubrock J. Rapp (Göttingen/DE), C. Güngör, M. Bockhorn (Hamburg/DE), T. Hackert, T. Hank O. Strobel, J. Werner (Heidelberg/DE), J. R. Izbicki (Hamburg/DE), S. A. Johnsen J. Gaedcke, J. Brockmöller, B. M. Ghadimi (Göttingen)
P 37 Developing MSC-based therapies for the treatment of pancreatic cancer
R. Zwacka, A. Mohr (Colchester/UK)
P 38 MicroRNAs as bile-based biomarkers in biliary-tract cancers
M. Mato Prado, A. E. Frampton (London/UK), N. Funel (Pisa/IT), E. López-Jiménez L. Castellano (London/UK), L. L. Meijer, G. Kazemier (Amsterdam/NL), L. R. Jiao J. Stebbing (London/UK), E. Giovannetti (Pisa/IT, Amsterdam/NL), J. Krell (London/UK)
Session 4 • Pancreatitis and pancreatic injury (P 39–P 48)
Chairs G. Beyer (München/DE), A. Arlt (Kiel/DE)
P 39 The effect of mast cell stabilizers on pain genesis and pain perception in acute and chronic pancreatitis
S. Klauss, S. Schorn, I. E. Demir, S. Teller, H. Friess, G. Ceyhan (Munich/DE)
P 40 Endoscopic drainage of walled-off pancreatic necrosis – a single center experience
R. Azevedo, H. Ribeiro, J. Pinto, F. Pereira, C. Leitão, A. Caldeira, E. Pereira, R. Sousa A. Banhudo (Castelo Branco/PT)
P 41 Minimally invasive and endoscopic methods of treatment of postnecrotic pseudocysts of pancreas
N. Omelchuk
(Ivano-Frankivsk/UA)
P 42 Step-up approach for walled-off pancreatic necrosis – endoscopic snapshot
R. Azevedo, H. Ribeiro, J. Pinto, F. Pereira, C. Leitão, A. Caldeira, E. Pereira, R. Sousa A. Banhudo (Castelo Branco/PT)
P 43 Surgical treatment of pancreaticopleural fistula in chronic pancreatitits
Y. Baravik
, S. Tretsyak, S. Rashchynski, N. Rashchynskay (Minsk/BY)
P 44 The effect of primary sensory neuron desensitization on experimental acute pancreatitis models
E. R. Bálint
, Z. Balla, L. Kiss, A. Molnár (Szeged/HU), C. Marsollier (Angers/FR) R. Marc (Nantes/FR), V. Venglovecz, J. Maléth (Szeged/HU), P. Hegyi, Z. Helyes (Pécs/HU) Z. Rakonczay Jr. (Szeged, Pésc/HU)
P 45 Autoimmune pancreatitis and inflammatory bowel disease – a riddle unwrapped
M. Kovacheva-Slavova
, S. Siminkovitch, P. Penchev, J. Genov, R. Mitova, P. Gecov B. Golemanov, B. Vladimirov (Sofia/BG)
P 46

Fluid volumes at 12 hours may be predictive of outcomes in acute Pancreatitis – A retrospective analysis
P. Nauka (Hempstead/US), J. Cagliani (Great Neck/US), G. Stoffels (Manhasset/US) A. Castenada (Great Neck/US), R. Gray, B. Villacres, T. Santos (Hempstead/US) G. Coppa, J. Nicastro, H. Rodriguez Rilo (Great Neck/US)

P 47 Outcomes of traumatic pancreatic injuries in pediatric and adult Patients – A retrospective review
T. Iurcotta, P. Addison, L. Amodu, M. Ackerman, D. Galvin, A. Glazer N. Christopherson, J. Prince, M. Bank, C. Sorrentino, J. Nicastro, G. Coppa, E. Molmenti H. Rodriguez Rilo (Manhasset/US)
P 48 Drain placement after pancreatic resections: a retrospective review
K. Fatakhova (New York, Manhasset/US), P. Addison, P. Nauka (Hempstead/US) L. Amodu (Hempstead, New York/US), N. Kohn (Manhasset/US) H. Rodriguez Rilo (Manhasset, New York/US)
Session 5 • Pancreatic cancer-clinical (P 49–P 60)
Chairs C. Michalski (Heidelberg/DE), M. Bockhorn (Hamburg/DE)
P 49 The severity of neural invasion predicts the incidence of local recurrence and has a major impact on overall and disease-free survival in pancreatic cancer
A. Brock, S. Schorn, I. E. Demir, C. Jäger, F. Scheufele, H. Friess, G. O. Ceyhan (Munich/DE)
P 50 Progressive Postresection Program (pPRP) after pancreatic Resection – First results of a randomized controlled trial
D. Weyhe, V. Uslar, S. Richter, B. Sahlmann, S. Janssen, F. Thode, F. Piastowski P. M. Million, L. M. Hartkemeyer, N. Tabriz, M. Droste (Oldenburg/DE)
P 51 Predictors for survival after ductal adeno carcinoma – R-status or circumferential resection margin
D. Weyhe, V. Uslar, I. Burkowski, A. Müller (Oldenburg/DE), A. Tannapfel (Bochum/DE)
P 52 The influence of preoperative endoscopic stent insertion into the common bile duct on postoperative outcome after a Traverso-Longmire Whipple surgical reconstruction – A retrospective analysis of prospectively collected clinical data
J. Weistra, D. Weyhe, V. Uslar (Oldenburg/DE)
P 53 Statin use decreases the risk of pancreatic cancer occurrence: a meta-analysis
L. Archibugi (Rome/IT), P. G. Arcidiacono (Milan/IT), G. Delle Fave, G. Capurso (Rome/IT)
P 54 Pancreatic cancer in women – Late onset of menopause, use of Hormonal Replacement Therapy, oral contraceptives an two-parity are protective factors
L. Archibugi, R. Valente, S. Stigliano, M. Roberto, C. Capalbo, P. Marchetti, G. Delle Fave G. Capurso (Rome/IT)
P 55 Open and laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) in patients with pancreatic ductal adenocarcinoma – technique and initial results
V. Lyadov, V. Milovanov, Z. Kovalenko (Moscow/RU)
P 56 Technical aspects of laparoscopic no-touch pancreatoduodenectomy
V. Lyadov, Z. Kovalenko, V. Milovanov (Moscow/RU)
P 57 Extension of fibrosis correlates with the prognosis for pancreatic ductal adenocarcinoma (PDA)
J. Müller, J. Kitz, J. Gaedcke, P. Ströbel, T. Beißbarth, M. Ghadimi (Göttingen/DE)
P 58 Comparison between CA19-9 elevation and imaging techniques in detection of pancreatic cancer recurrence after curative surgery andm adjuvant chemotherapy
A. Azizian, F. Rühlmann, T. Krause, A. König, X. Schulz, M. Ghadimi J. Gaedcke (Göttingen/DE)
P 59 Postoperative results after pylorus-preserving pancreaticoduod nectomy using delpero's omental flap
M. Thülig, C. Gerdes, S. Elhabash, M. Sorleto, B. Gerdes (Minden/DE)
P 60 Intensified histopatholgocial work-up after pancreatic head resection reveals relevant prognostic markers
J. Gaedcke, M. Oldani, T. Steffen, J. Kitz, A. Azizian A. König, P. Ströbel, T. Beißbarth M. Ghadimi (Göttingen/DE)